Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 136-146

  Haase, C L ^a   Frikke Schmidt, R ^a   Nordestgaard, B G ^b,c   Kateifides, A K ^d,e   Kardassis, D ^d   Nielsen, L B ^a,f   Andersen, C B ^a   Kober L ^a   Johnsen, A H ^a   Grande, P ^a   Zannis, V I ^d,e   Tybjaerg Hansen A ^a,c  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d UNIVERSITY OF CRETE   (Greece)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apolipoproteins; Cardiovascular disease; Genetics; Lipoproteins; Mortality

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANIMAL EXPERIMENT; APOA1 GENE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ELECTRON MICROSCOPY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HEART INFARCTION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; SURVIVAL TIME; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION STUDY; VIRAL GENE DELIVERY SYSTEM;

ADULT; AGED; ANIMALS; APOLIPOPROTEIN A-I; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MICE; MIDDLE AGED; MUTATION; MYOCARDIAL ISCHEMIA; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 79960241608     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02381.x     Document Type: Article

References (27)

1. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
2. Frikke-Schmidt R, Nordestgaard BG, Stene MCA et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 2524-32.
3. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
4. Freiberg JJ, Tybjærg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-52.
5. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high-density lipoproteins. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York, NY: McGraw-Hill, 2001; 2915-36.
6. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002; 12: 121-8.
7. Zannis VI, Koukos G, Drosatos K et al. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med 2008; 40: 14-28.
8. Haase CL, Tybjærg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010; 95: E500-10.
9. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21year follow-up of 12000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23: 620-6.
10. Julian DG, Bertrand ME, Hjalmarson Å, Fox K, Simoons ML. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413.
11. van Gameren II, Hazenberg BPC, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54: 2015-21.
12. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109: 181-8.
13. Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 2005; 118: 1287e1-e7.
14. Wittich CM, Neben-Wittich MA, Mueller PS, Gertz MA, Edwards WD. Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis. Cardiovasc Pathol 2007; 16: 75-8.
15. Suwaidi JA, Velianou JL, Gertz MA et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999; 131: 838-41.
16. Whitaker DC, Tungekar MF, Dussek JE. Angina with a normal coronary angiogram caused by amyloidosis. Heart 2004; 90: e54.
17. Ishikawa Y, Ishii T, Masuda S et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int 1996; 46: 189-94.
18. Navab M, Reddy S, van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50(Suppl): S145-9.
19. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9: 493-8.
20. Pepys MB. Amyloidosis. Annu Rev Med 2006; 57: 223-41.
21. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005; 12: 75-87.
22. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2001; 52: 347-61.
23. Amarzguioui M, Mucchiano G, Häggqvist B et al. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun 1998; 242: 534-9.
24. Mucchiano GI, Häggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001; 193: 270-5.
25. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
26. Miccoli R, Bertolotto A, Navalesi R et al. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 1996; 94: 1622-8.
27. Recalde D, Velez-Carrasco W, Civeira F et al. Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-I(Zaragoza) (L144R). Atherosclerosis 2001; 154: 613-23.